Pricing
  1. JP-listed companies
  2. Perseus Proteomics Inc.
  3. Financials
  4. Revenue

Perseus Proteomics Inc. (4882)

Market cap
¥3.3B
P/E ratio
Perseus Proteomics develops high-performance antibodies for cancer treatment and drug discovery using proprietary technology from the University of Tokyo.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue (Million JPY)YoY (%)
Mar 31, 2025120+19.89%
Mar 31, 2024100+6.58%
Mar 31, 202394+30.96%
Mar 31, 202272+5.86%
Mar 31, 202168-20.77%
Mar 31, 202086-68.92%
Mar 31, 2019276-9.22%
Mar 31, 2018304+7.57%
Mar 31, 2017283-50.43%
Mar 31, 2016570

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat